CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE
化疗 /- 霍奇金病的额外化疗和/或 XRT
基本信息
- 批准号:7607510
- 负责人:
- 金额:$ 0.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-12-01 至 2007-09-16
- 项目状态:已结题
- 来源:
- 关键词:BloodChemotherapy-Oncologic ProcedureChildClinical TrialsCombination ChemotherapyComputer Retrieval of Information on Scientific Projects DatabaseCountDatabasesDrug usageFilgrastimFundingGrantHodgkin DiseaseInfusion proceduresInjection of therapeutic agentInstitutionNational Cancer InstituteNewly DiagnosedOral cavityPatientsPharmaceutical PreparationsPhase III Clinical TrialsPhysician Data QueryPrednisoneRadiation therapyRandomizedResearchResearch PersonnelResourcesSourceTimeUnited States National Institutes of HealthWeekWorkcancer cellchemotherapydaykillings
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
(Clinical trial summary from the National Cancer Institute's PDQ¿ database)
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
This randomized Phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease.
Patients will receive infusions or injections of combination chemotherapy on Days 1-3 and 8. They will also receive prednisone by mouth two or three times a day on Days 1-7. Beginning on Day 4, patients will also receive injections of filgrastim once a day (except Day 8) until blood counts return to normal.
Treatment may be repeated every 3 weeks for up to two courses. Patients will then be assigned to one of two groups. Patients in Group 1 will receive two additional courses of the initial chemotherapy regimen, followed by either radiation therapy or no further treatment. Patients in Group 2 will be randomly assigned to one of two groups to receive either two courses of another chemotherapy regimen plus two additional courses of the initial chemotherapy regimen, followed by radiation therapy OR two additional courses of the initial chemotherapy regimen followed by radiation therapy.
Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter.
这个子项目是许多利用
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
(临床试验总结来自国家癌症研究所的PDQ数据库)
化疗中使用的药物使用不同的方法来阻止癌细胞分裂,使它们停止生长或死亡。给予不同组合的药物可能会杀死更多的癌细胞。放射治疗使用高能x射线来破坏癌细胞。目前尚不清楚化疗是否更有效,是否有额外的化疗和/或放射治疗在治疗霍奇金病。
这项随机的III期试验正在研究不同的化疗方案,同时进行或不进行放射治疗,以比较它们在治疗新诊断的霍奇金病儿童方面的效果。
患者将在第1-3天和第8天接受联合化疗的输注或注射。他们还将在第1-7天口服泼尼松,每天两次或三次。从第4天开始,患者还将接受非格司亭注射,每天一次(第8天除外),直至血细胞计数恢复正常。
治疗可以每3周重复一次,最多两个疗程。然后将患者分配到两组之一。第1组的患者将接受两个额外的初始化疗方案疗程,随后进行放射治疗或不进行进一步治疗。第2组的患者将被随机分配到两组中的一组,接受两个疗程的另一种化疗方案加两个额外疗程的初始化疗方案,随后接受放疗,或接受两个额外疗程的初始化疗方案,随后接受放疗。
每3个月对患者进行一次评价,持续2年,每6个月评价一次,持续3年,此后每年评价一次。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOUSIF H MATLOUB其他文献
YOUSIF H MATLOUB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOUSIF H MATLOUB', 18)}}的其他基金
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL
儿童不同联合化疗方案与所有患者的比较
- 批准号:
7607499 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
高风险 B 前体急性淋巴细胞白血病
- 批准号:
7607545 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
COMPARISON OF CHEMOTHERAPY REGIMENS IN CHILDREN WITH RHABDOMYOSARCOMA
横纹肌肉瘤儿童化疗方案的比较
- 批准号:
7607544 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
标准风险 B 前体急性淋巴细胞白血病
- 批准号:
7607542 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA
通过间隔压缩对尤文氏肉瘤进行强化化疗
- 批准号:
7607505 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS
中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究
- 批准号:
7607495 - 财政年份:2006
- 资助金额:
$ 0.3万 - 项目类别:
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS
中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究
- 批准号:
7204321 - 财政年份:2005
- 资助金额:
$ 0.3万 - 项目类别:
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL
儿童不同联合化疗方案与所有患者的比较
- 批准号:
7204344 - 财政年份:2005
- 资助金额:
$ 0.3万 - 项目类别:
PRIMARY SURGICAL THERAPY FOR BIOLOGICALLY DEFINED LOW-RISK NEUROBLASTOMA
生物学定义的低风险神经母细胞瘤的初步手术治疗
- 批准号:
7204350 - 财政年份:2005
- 资助金额:
$ 0.3万 - 项目类别:
RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS
中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究
- 批准号:
7375483 - 财政年份:2005
- 资助金额:
$ 0.3万 - 项目类别: